'Shedding' light on mechanisms of hyperphosphatemic vascular dysfunction

Kidney International

Volumn 83, Issue 2, 2013, Pages 187-189

  Burger, Dylan ^a   Levin, Adeera ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; LIPOCORTIN 2; PHOSPHATE;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR RISK; CELL ADHESION; CELL DIFFERENTIATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; ENDOTHELIUM CELL; HYPERPHOSPHATEMIA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOBLAST; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

EID: 84873340917     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.416     Document Type: Note

References (13)

1. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
2. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
3. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
4. Ellam TJ, Chico TJ. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012; 220: 310-318.
5. Hruska K, Mathew S, Lund R et al. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int Suppl 2011; S9-S13.
6. Neven E, D'Haese PC. Vascular calcification in chronic renal failure. Circ Res 2011; 108: 249-264.
7. Mathew S, Lund RJ, Strebeck F et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130.
8. Six I, Maizel J, Barreto FC et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 2012; 96: 130-139.
9. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
10. Di Marco GS, König M, Stock C et al. High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int 2012; 83: 213-222.
11. Burger D, Touyz RM. Cellular biomarkers of endothelial health: microparticles, endo-thelial progenitor cells, and circulating endo-thelial cells. J Am Soc Hypertens 2012; 6: 85-99.
12. Flood EC, Hajjar KA. The annexin A2 system and vascular homeostasis. Vascul Pharmacol 2011; 54: 59-67.
13. Burger D, Kwart DG, Montezano AC et al. Microparticles induce cell cycle arrest through redox-sensitive processes in endothelial cells: implications in vascular senescence. J Am Heart Assoc [online] 2012; 1: e001842.